Harbour BioMed and AstraZeneca Forge $4.7 Billion Antibody Discovery Deal

Harbour BioMed has secured a global strategic collaboration with AstraZeneca to advance next-generation multi-specific antibody therapies in immunology and oncology. The deal includes an equity investment of $105 million by AstraZeneca and the option to license multiple programs powered by Harbour BioMed’s proprietary Harbour Mice® technology platform. AstraZeneca will initially gain licensing options for two preclinical immunology programs, with additional targets to be nominated. The collaboration could see Harbour BioMed receive $175 million upfront and up to $4.4 billion in milestone payments, making it a landmark agreement in the biopharma sector.

As part of the partnership, Harbour BioMed will establish an innovation center in Beijing, China, co-located with AstraZeneca, fostering joint research initiatives. AstraZeneca will also acquire 9.15% newly issued shares of Harbour BioMed, reinforcing a long-term commitment to innovation. Jingsong Wang, MD, PhD, CEO of Harbour BioMed, highlighted the potential of this partnership, stating, "This collaboration positions us as a leader in multi-specific biologics, accelerating breakthrough therapies for patients in need."